EpiPen®
Trainer Pen

The EpiPen® Trainer Pen is easy to tell apart from EpiPen®. The label clearly states EpiPen® Trainer and it is pale blue and grey in colour.

The Trainer Pen:

  • Is reusable so patients can practice as many times as they like.
  • Works in the same way as the EpiPen® but doesn't contain a needle or any adrenaline.

How to use

1. Remove the blue safety cap.

2. Jab the orange tip firmly into the outer thigh and hold in place for 3 seconds.


To reset the Trainer Pen after use, first replace the blue safety cap. Then place the orange tip on a hard surface, squeeze the sides of the orange tip and push down.

We recommend that patients show their friends, family, carers or colleagues how to use the Trainer Pen so they are familiar with it in case of any emergency.

Need an EpiPen® Trainer?

Please contact us on +353 1 8711600 or email enquiry.ire@viatris.com

YES

The website you are trying to access is designed for healthcare professionals, the content is not designed for the general public.


Are you a healthcare professional registered in Ireland?

YES
NO

EpiPen® (adrenaline) and EpiPen® Junior (adrenaline) Auto-Injectors are indicated in the emergency treatment of severe allergic reactions (anaphylaxis) to insect stings or bites, foods, drugs and other allergens, as well as idiopathic or exercise induced anaphylaxis.

Product subject to medical prescription.

This site is designed for healthcare professionals registered in Ireland, if you are not a healthcare professional registered in Ireland, please
click here to visit our patient website.

For further information please consult:

EpiPen (adrenaline) 300 micrograms solution for injection in pre-filled pen, Summary of Product Characteristics

EpiPen Junior (adrenaline) 150 micrograms solution for injection in pre-filled pen, Summary of Product Characteristics

This website is owned and managed by Viatris.

@2023 Viatris. All rights reserved.

Viatris, Newenham Court, Northern Cross, Malahide Road, Dublin 17, Ireland.

Job Code: EPI-2023-0506
Date of Preparation: December 2023

Reporting of adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.


Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system HPRA Pharmacovigilance, Website: www.hpra.ie


Adverse reactions/events should also be reported to the marketing authorisation holder at email address: pv.ireland@viatris.com or phone 0044 (0) 800 1218267.

hcp popup title

Viatris Connect is an online platform for UK health Professionals.

Across the website you will find news, blogs and product information.

Register to Viatris Connect today

Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.

REGISTER NOW